Vous êtes ici

Onglets principaux

Profil

Dr. Allan Sniderman

Affiliation

McGill University

Académie ou Collège

Académie des sciences

Année d'admission

2009

Domaines d’expertise

Cardiovascular disease, apoB, risk factors, obesity,

Allan Sniderman introduced apoB into clinical practice worldwide as the key index for treating elevated cholesterol levels thus saving many lives. In May 2008, the American Diabetes Association and College of Cardiology jointly stated that apoB is superior to other cholesterol markers. His work on the regulation of the composition, number, and hepatic secretion of apoB particles, and the regulation of fatty acid transport in adipocytes provided a physiologic basis for his seminal clinical finding.

------------------

SNIDERMAN, Allan David -McGill University Health Centre
Allan Sniderman introduced apoB into clinical practice worldwide as the key index for treating elevated cholesterol levels thus saving many lives. In 1980 he first published that apoB was a better index of vascular disease risk than LDL cholesterol; and confirmed this in subsequent epidemiologic studies. In May 2008, the American Diabetes Association and College of Cardiology jointly stated that apoB is superior to other cholesterol markers. His work on the regulation of the composition, number, and hepatic secretion of apoB particles, and the regulation of fatty acid transport in adipocytes provided a physiologic basis for his seminal clinical finding.